IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Patent Application of |) |
|---------------------------------------------|--------------------------|
| |) |
| Larry S. BARAK et al. |) Group Art Unit: 1645 |
| |) |
| Application No.: 10/054,616 |) Examiner: Unassigned |
| |) |
| Filed: January 22, 2002 |) Confirmation No.: 7096 |
| |) |
| For: Constitutively Desensitized G Protein- |) |
| Coupled Receptors |) |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

· Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following co-pending applications in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the co-pending applications cited is enclosed.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the co-pending applications are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

By citation to the copending applications, confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending applications under 35 U.S.C. § 122.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404

Alexandria, VA 22313-1404

Phone: (919) 941-9240

Date: July 18 2002

Registration No. 45,774

BEST AVAILABLE COPY

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| ATTORNEY'S DKT NO. | APPLICATION NO. |
|-----------------------|-----------------|
| 033072-022 | 10/054,616 |
| APPLICANT | |
| Larry S. BARAK et al. | |
| FILING DATE | GROUP |
| January 22, 2002 | 1645 |

| | | | U.S. PATENT DOC | JMENTS | | | | | | |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------------------------------------------|-------------------------------|-----------|------------------------------------|-----------------------|--------------|--|--|
| | U.S. Patent [| | | | | | | | | |
| Examiner Initials | Number | Kind Code (if known) | | Name of Patentee or Applicant | | | ation | | | |
| IIIIIIII | Mannet | (II KHUWII) | UI CILEG D | of Cited Document | | | | (MM-DD-YYYY) | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | <u> </u> | | | | | | | | | |
| | | | | | | | | | | |
| | | - | W | | | | | | | |
| | | | | | | | | - | | |
| | | | | 75 . | | | | | | |
| | | | | _ | | | | | | |
| 2 | | | | T-160 | | | | | | |
| - | | | | | _ | | | | | |
| | | FO | REIGN PATENT DO | CUMENTS | | | | | | |
| 100.0 | Foreign Patent | Document | | | | | | | | |
| Examiner Initials | Kind Code Number (if known) Countr | | Country | • | | ate of Publication (MM-DD-YYYY) | Translation Yes no | | | |
| · · · · · · · · · · · · · · · · · · · | Tramber | (II KIIOWII) | Country | | | IMM-DD-1111) | res | no | | |
| ** | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | NON PA | ATENT LITERATUR | DOCUME | NTS | | | | | |
| Examiner Initials | Include item (book, | name of author (magazine, journ | (in CAPITAL LETTERS), nal, serial, symposium, c publisher, city and/or co | atalog, etc.), d | ate, page | e(s), volume-issue numb | he per(s), | | | |
| | U.S. Patent Applica November 5, 2001, | | ,844, Robert H. Oakley, | | | | Filed or | 1 | | |
| | U.S. Patent Application No. 09/469,554, Laura M. Bohn, et al., Inhibition of B-arrestin Mediated Effects Prolongs and Potentiates Opioid Receptor-Mediated Analgesia, Filed on December 22, 1999, attorney docket no. 033072-017. | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | - | | | | | |
| Examiner | <u> </u> | | | Data | ſ | | | | | |
| Examiner Signature | | | | Date Considered | | | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.